Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 3/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.50 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705060 | 1.00 | IKBKB (0.53) | IKBKBPRKCZSMYD3ROCK1PRMT3 | |
| SCHEMBL1705061 | 1.00 | IKBKB (0.53) | IKBKBPRKCZSMYD3ROCK1PRMT3 | |
| SCHEMBL1705148 | 0.83 | IKBKB (0.62) | IKBKBPRKCZSMYD3ROCK1PRMT3 | |
| SCHEMBL1705720 | 0.83 | IKBKB (0.62) | IKBKBPRKCZSMYD3ROCK1PRMT3 | |
| SCHEMBL1705149 | 0.83 | IKBKB (0.62) | IKBKBPRKCZSMYD3ROCK1PRMT3 | |
| SCHEMBL1705018 | 0.81 | IKBKB (0.56) | IKBKBPRKCZSMYD3ROCK1PRMT3 | |
| SCHEMBL1705019 | 0.81 | IKBKB (0.56) | IKBKBPRKCZSMYD3ROCK1PRMT3 | |
| SCHEMBL1704953 | 0.80 | PRMT3 (0.44) | IKBKBPRKCZROCK1PRMT3ROCK2 | |
| SCHEMBL1705012 | 0.80 | PRMT3 (0.44) | IKBKBPRKCZROCK1PRMT3ROCK2 | |
| SCHEMBL1705554 | 0.80 | PRMT3 (0.44) | IKBKBPRKCZROCK1PRMT3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8609691-B2 | Cyclohexylamin isoquinolone derivatives | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-1912949-B1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| EP-1912949-B1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | MYLK, MYLK2, ROCK1 | IKBKB 727/4885PRKCZ 180/4885SMYD3 2294/4885 |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | MYLK2, MYLK, MYLK3 | IKBKB 766/4885PRKCZ 104/4885SMYD3 3210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.